Bevacizumab biosimilar (Elea)

贝伐珠单抗生物类似药 (Elea)

Report date: 2022/03/14 16:56:43

Base Information

Drug NameBevacizumab biosimilar (Elea)
Drug Alias Name贝伐人源化单抗生物仿制药 (Elea)贝伐赛珠单抗生物仿制药 (Elea)贝伐珠单抗生物仿制药 (Elea)贝伐单抗生物仿制药 (Elea)Lumiere
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsMacular Degeneration
Approved Indications in ChinaN/A
Original Approved Country/TerritoryArgentina
Original Approved Date2018/04/26
Country/TerritoryArgentina
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLaboratorio Elea Phoenix Sa
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A